Vomstein Kilian, Feil Katharina, Strobel Laura, Aulitzky Anna, Hofer-Tollinger Susanne, Kuon Ruben-Jeremias, Toth Bettina
Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
Department of Gynecological Endocrinology and Fertility Disorders, Ruprecht-Karls University Heidelberg, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany.
J Clin Med. 2021 Feb 20;10(4):869. doi: 10.3390/jcm10040869.
Around 1-5% of all couples experience recurrent pregnancy loss (RPL). Established risk factors include anatomical, genetic, endocrine, and hemostatic alterations. With around 50% of idiopathic cases, immunological risk factors are getting into the scientific focus, however international guidelines hardly take them into account. Within this review, the current state of immunological risk factors in RPL in international guidelines of the European Society of Reproduction and Embryology (ESHRE), American Society of Reproductive Medicine (ASRM), German/Austrian/Swiss Society of Obstetrics and Gynecology (DGGG/OEGGG/SGGG) and the Royal College of Obstetricians and Gynecologists (RCOG) are evaluated. Special attention was drawn to recommendations in the guidelines regarding diagnostic factors such as autoantibodies, natural killer cells, regulatory T cells, dendritic cells, plasma cells, and human leukocyte antigen system (HLA)-sharing as well as treatment options such as corticosteroids, intralipids, intravenous immunoglobulins, aspirin and heparin in RPL. Finally, the current state of the art focusing on both diagnostic and therapeutic options was summarized.
约1%至5%的夫妇经历复发性流产(RPL)。已确定的风险因素包括解剖学、遗传学、内分泌学和止血方面的改变。约50%的病例病因不明,免疫风险因素正成为科学研究的焦点,然而国际指南几乎未将其纳入考量。在本综述中,对欧洲人类生殖与胚胎学会(ESHRE)、美国生殖医学学会(ASRM)、德国/奥地利/瑞士妇产科学会(DGGG/OEGGG/SGGG)以及皇家妇产科医师学院(RCOG)国际指南中RPL免疫风险因素的现状进行了评估。特别关注了指南中关于自身抗体、自然杀伤细胞、调节性T细胞、树突状细胞、浆细胞和人类白细胞抗原系统(HLA)共享等诊断因素的建议,以及RPL中皮质类固醇、脂肪乳剂、静脉注射免疫球蛋白、阿司匹林和肝素等治疗选择。最后,总结了聚焦于诊断和治疗选择的当前技术水平。